PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30858408-5	2019	Here we report that direct TRPV1 activation by localized trans-tympanic (TT) or oral administration of capsaicin (TRPV1 agonist) prevents cisplatin ototoxicity by sustained increased activation of pro-survival transcription factor signal transducer and activator of transcription (STAT3) in the Wistar rat.	Cisplatin	138-147	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	27-32	
32138533-0	2020	Corydalis saxicola Alkaloids Attenuate Cisplatin-Induced Neuropathic Pain by Reducing Loss of IENF and Blocking TRPV1 Activation.	Cisplatin	39-48	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	112-117	
32138533-11	2020	Moreover, CSBTA could normalize the overexpression levels of p-p38 and Transient receptor potential vanilloid receptor (TRPV1) induced by cisplatin in DRG, trigeminal ganglion (TG), spinal cord, and foot of rats.	Cisplatin	138-147	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	120-125	
30858408-4	2019	Upregulation of cochlear TRPV1 expression is related to cisplatin-mediated ototoxicity.	Cisplatin	56-65	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	25-30	
30858408-5	2019	Here we report that direct TRPV1 activation by localized trans-tympanic (TT) or oral administration of capsaicin (TRPV1 agonist) prevents cisplatin ototoxicity by sustained increased activation of pro-survival transcription factor signal transducer and activator of transcription (STAT3) in the Wistar rat.	Cisplatin	138-147	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	114-119	
19052196-9	2008	These data provide a link between NOX3 and TRPV1 in cisplatin-induced hearing loss and suggest that targeting these proteins for knockdown by siRNA could serve as a novel approach in treating cisplatin ototoxicity.	Cisplatin	52-61	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	43-48	
31139213-13	2019	In conclusion, tesaglitazar produced significant analgesic effects in STZ and cisplatin-induced neuropathy, possibly by modulating TRPV1 receptor activity.	Cisplatin	78-87	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	131-136	
20712533-1	2011	Transient receptor potential vanilloid 1 (TRPV1) is implicated in cisplatin ototoxicity.	Cisplatin	66-75	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	0-40	
20712533-1	2011	Transient receptor potential vanilloid 1 (TRPV1) is implicated in cisplatin ototoxicity.	Cisplatin	66-75	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	42-47	
20712533-3	2011	Knockdown of TRPV1 by short interfering RNA protected against cisplatin ototoxicity.	Cisplatin	62-71	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	13-18	
19052196-0	2008	Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat.	Cisplatin	82-91	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	30-70	
19052196-4	2008	In this study, we show that TRPV1 is coregulated along with the NADPH oxidase isoform, NOX3, by cisplatin.	Cisplatin	96-105	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	28-33	
19052196-8	2008	Treatment of UB/OC-1 cultures with short interfering RNA (siRNA) against either TRPV1 or NOX3 reduced cisplatin-induced apoptosis, while round window application of TRPV1 siRNA to rats reduced TRPV1 expression, decreased damage to outer hair cells and reduced cisplatin-induced hearing loss.	Cisplatin	102-111	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	80-85